Christopher Breed
Papers
1
Total Citations
133
H-Index
1
About
Dr. Christopher Breed is a leading clinical researcher in gynecologic oncology, with a focused expertise in perioperative care and venous thromboembolism (VTE) prevention. His most impactful work challenges standard-of-care protocols for patients undergoing surgery for gynecologic malignancies. In his landmark 2020 study, cited over 130 times, Dr. Breed demonstrated that apixaban, a direct oral anticoagulant, is as safe and effective as the standard injectable enoxaparin for preventing postoperative blood clots. This finding is critical for improving patient quality of life, as it offers a more affordable, oral alternative that dramatically increases medication adherence compared to the costly 28-day injection regimen. By providing robust evidence for a simpler thromboprophylaxis strategy, his research directly influences clinical guidelines and reduces the burden on patients recovering from major cancer surgery. Dr. Breed’s work is a prime example of how rigorous comparative effectiveness research can translate into tangible improvements in patient-centered care.
Research Focus
Key Achievements
Top Papers
- 1